Seeyond Neurocrine Biosciences Inc Transaction History

Seeyond

$1.03 Billion
Q4 2022

A detailed history of Seeyond transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Seeyond holds 20,524 shares of NBIX stock, worth $2.58 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares

20,524

Previous 23,527 12.76%

Holding current value

$2.58 Million

Previous $2.5 Million 1.88%

% of portfolio

0.24%

Previous 0.3%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$106.72 - $127.06 $320,480 - $381,561	-3,003 Reduced 12.76%	20,524 $2.45 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $70,310 - $82,366	764 Added 3.36%	23,527 $2.5 Million
Q2 2022 Aug 12, 2022	BUY	$75.79 - $100.07 $296,338 - $391,273	3,910 Added 20.74%	22,763 $2.22 Million
Q1 2022 May 13, 2022	BUY	$72.45 - $94.81 $572,065 - $748,619	7,896 Added 72.06%	18,853 $1.77 Million
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $9,565 - $10,992	-111 Reduced 1.0%	10,957 $1.05 Million
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $4,471 - $5,113	50 Added 0.45%	11,068 $1.08 Million
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $2.31 Million - $3.16 Million	-26,431 Reduced 70.58%	11,018 $1.07 Million
Q4 2020 Feb 12, 2021	SELL	$86.91 - $108.33 $1.08 Million - $1.34 Million	-12,373 Reduced 24.83%	37,449 $3.59 Million
Q3 2020 Nov 12, 2020	SELL	$96.16 - $135.15 $755,432 - $1.06 Million	-7,856 Reduced 13.62%	49,822 $4.79 Million
Q2 2020 Aug 13, 2020	BUY	$85.09 - $130.36 $4.53 Million - $6.94 Million	53,232 Added 1197.3%	57,678 $7.04 Million
Q1 2020 May 14, 2020	SELL	$75.11 - $113.76 $2,628 - $3,981	-35 Reduced 0.78%	4,446 $128,000
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $388,950 - $531,312	4,481 New	4,481 $219,000

Others Institutions Holding NBIX

# of Institutions

625

Shares Held

94.2M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Seeyond, based on Form 13F filings with the SEC.

News

Stay updated on Seeyond with notifications on news.

Account